Sarizotan
PreclinicalSmall molecule
EMD SeronoSarizotan is one of 17 small molecule programs targeting Tardive Dyskinesia. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Tardive Dyskinesia
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Zyprexa
MMODAG GmbH
Approved
Austedo
TevaApproved
Risperdal
WWim Janssens
Approved
Barhemsys
AAcacia Pharma Ltd
Approved
Abilify
OtsukaApproved
Reminyl
WWim Janssens
Approved
Eicosapentaenoic Acid
SS.L.A. Pharma AG
Approved
Inderal
Mylan Pharmaceuticals IncPhase 3
Piracetam
UCBPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Parkinson's Disease2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sarizotan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company